Wei Zhuang

Dec 9, 2024 | mdpi.com | Wei Zhuang |Yunhong Zhang |Yuan Wang |Kaiyang He

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Mar 25, 2024 | onlinelibrary.wiley.com | Jie Zhao |Wei Zhuang |Boyang Sun |Hua Bai

INTRODUCTION The striking development of immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought obvious curative effect and prolonged overall survival (OS) for advanced non-small cell lung cancer (NSCLC) while some patients do not obtain benefit from immunotherapy.1 In response to the urgent need for precision medicine, determination of an optimal biomarker to enrich beneficial population of immunotherapy is essential to enhance healthcare cost-effectiveness.2 Programmed...

May 12, 2023 | bpspubs.onlinelibrary.wiley.com | Wei Zhuang |Jiabing Xu |Ye E Wu |Jianhui Yang

Abstract Aims Nirmatrelvir is an antiviral drug with a novel mechanism of action, targeting the 3-CL protease, and is used in the treatment of COVID-19. However, the potential side effects have not yet been fully studied. The aim of this study was to identify potential safety signals of nirmatrelvir by analysing post-marketing safety data based on the largest publicly available worldwide pharmacovigilance database.